Jefferies downgraded Cargo Therapeutics (CRGX) to Hold from Buy with a price target of $3, down from $32. The company announced the “surprising and disappointing news” that it will discontinue its lead Phase II firi-cel due to safety and durability, the analyst tells investors in a research note. The firm says this is a reset and that Cargo’s next-generation tri-specific CAR-T CRG-023 is very early stage.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRGX: